SOLENO THERAPEUTICS INC

Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for rare diseases. The company's primary asset is Diazoxide Choline Extended-Release tablets, an oral formulation currently in Phase III clinical trials for Prader-Willi Syndrome, a rare genetic disorder characterized by hyperphagia and metabolic dysfunction. The company has not generated meaningful product revenues to date, as its lead candidate remains in development.

The company operates as a pre-commercial entity with a pipeline focused on rare metabolic and genetic conditions. Soleno maintains its primary operations in Redwood City, California, with a workforce of 152 full-time employees. The organization was incorporated in Delaware in 1999, initially operating under the name Capnia, Inc. before rebranding as Soleno Therapeutics in May 2017 to reflect its shifted strategic focus toward rare disease therapeutics.